BR112016021012A2 - composições farmacêuticas de compostos terapeuticamente ativos. - Google Patents

composições farmacêuticas de compostos terapeuticamente ativos.

Info

Publication number
BR112016021012A2
BR112016021012A2 BR112016021012-3A BR112016021012A BR112016021012A2 BR 112016021012 A2 BR112016021012 A2 BR 112016021012A2 BR 112016021012 A BR112016021012 A BR 112016021012A BR 112016021012 A2 BR112016021012 A2 BR 112016021012A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
active compounds
therapeutically active
therapeutically
compounds
Prior art date
Application number
BR112016021012-3A
Other languages
English (en)
Other versions
BR112016021012B1 (pt
Inventor
Gu Chong-Hui
Original Assignee
Agios Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals, Inc. filed Critical Agios Pharmaceuticals, Inc.
Priority to BR122023021440-4A priority Critical patent/BR122023021440A2/pt
Priority to BR122023021436-6A priority patent/BR122023021436A2/pt
Publication of BR112016021012A2 publication Critical patent/BR112016021012A2/pt
Publication of BR112016021012B1 publication Critical patent/BR112016021012B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ecology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112016021012-3A 2014-03-14 2015-03-13 Uso de uma composição farmacêutica de (s)-n-((s)-1-(2-clorofenil)-2-((3,3-difluorciclobutil)amino)-2-oxoetil)-1-(4-cianopiridin-2-il)-n-(5-fluorpiridin-3-il) -5-oxopirrolidina-2- carboxamida e seus sais para tratamento de tumores sólidos avançados BR112016021012B1 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR122023021440-4A BR122023021440A2 (pt) 2014-03-14 2015-03-13 Composição farmacêutica de compostos terapeuticamente ativos
BR122023021436-6A BR122023021436A2 (pt) 2014-03-14 2015-03-13 Formas cristalinas e composição farmacêutica de compostos terapeuticamente ativos

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461953480P 2014-03-14 2014-03-14
US61/953,480 2014-03-14
PCT/US2015/020346 WO2015138837A1 (en) 2014-03-14 2015-03-13 Pharmaceutical compositions of therapeutically active compounds

Publications (2)

Publication Number Publication Date
BR112016021012A2 true BR112016021012A2 (pt) 2018-08-07
BR112016021012B1 BR112016021012B1 (pt) 2024-01-23

Family

ID=54072439

Family Applications (3)

Application Number Title Priority Date Filing Date
BR122023021436-6A BR122023021436A2 (pt) 2014-03-14 2015-03-13 Formas cristalinas e composição farmacêutica de compostos terapeuticamente ativos
BR122023021440-4A BR122023021440A2 (pt) 2014-03-14 2015-03-13 Composição farmacêutica de compostos terapeuticamente ativos
BR112016021012-3A BR112016021012B1 (pt) 2014-03-14 2015-03-13 Uso de uma composição farmacêutica de (s)-n-((s)-1-(2-clorofenil)-2-((3,3-difluorciclobutil)amino)-2-oxoetil)-1-(4-cianopiridin-2-il)-n-(5-fluorpiridin-3-il) -5-oxopirrolidina-2- carboxamida e seus sais para tratamento de tumores sólidos avançados

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BR122023021436-6A BR122023021436A2 (pt) 2014-03-14 2015-03-13 Formas cristalinas e composição farmacêutica de compostos terapeuticamente ativos
BR122023021440-4A BR122023021440A2 (pt) 2014-03-14 2015-03-13 Composição farmacêutica de compostos terapeuticamente ativos

Country Status (27)

Country Link
US (1) US20170007661A1 (pt)
EP (1) EP3116491B1 (pt)
JP (3) JP6524119B2 (pt)
KR (1) KR102458157B1 (pt)
CN (2) CN106163507B (pt)
AU (2) AU2015229212B2 (pt)
BR (3) BR122023021436A2 (pt)
CA (1) CA2942070A1 (pt)
CY (1) CY1125205T1 (pt)
DK (1) DK3116491T3 (pt)
EA (2) EA034366B1 (pt)
ES (1) ES2881858T3 (pt)
HR (1) HRP20211233T1 (pt)
HU (1) HUE055209T2 (pt)
IL (1) IL247721B (pt)
LT (1) LT3116491T (pt)
MA (1) MA39725B1 (pt)
MX (2) MX2016011865A (pt)
NZ (1) NZ723860A (pt)
PH (1) PH12016501788A1 (pt)
PL (1) PL3116491T3 (pt)
PT (1) PT3116491T (pt)
RS (1) RS62178B1 (pt)
SI (1) SI3116491T1 (pt)
UA (1) UA122962C2 (pt)
WO (1) WO2015138837A1 (pt)
ZA (1) ZA201606134B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
AU2015229214B2 (en) 2014-03-14 2019-07-11 Les Laboratoires Servier Pharmaceutical compositions of therapeutically active compounds
HRP20211790T1 (hr) 2015-10-15 2022-03-04 Les Laboratoires Servier Kombinirana terapija za liječenje maligniteta
BR112018007671B1 (pt) 2015-10-15 2023-10-17 Les Laboratoires Servier Usos de um inibidor da idh1 e combinações
JP6852073B2 (ja) 2015-12-04 2021-03-31 アジオス ファーマシューティカルズ， インコーポレイテッド 悪性病変を処置する方法
WO2017123808A1 (en) * 2016-01-15 2017-07-20 The J. David Gladstone Institutes Methods of treating disease by metabolic control of t-cell differentiation
MX2018010252A (es) 2016-02-26 2019-01-31 Celgene Corp Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
WO2018085486A1 (en) * 2016-11-02 2018-05-11 University Of Cincinnati Compositions and methods for treating patients suffering from glioma or leukemia
EP3570839B1 (en) * 2017-01-20 2020-12-02 Constellation Pharmaceuticals, Inc. Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
FI3686191T3 (fi) * 2017-09-22 2023-01-31 Kiteinen sulfamidiyhdiste
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
MX2021000068A (es) * 2018-07-06 2021-03-25 Agios Pharmaceuticals Inc Formas y composiciones farmaceuticas de ivosidenib.
US20210069113A1 (en) * 2019-09-11 2021-03-11 Modavar Pharmaceuticals LLC Solid unit dosage form for dose individualized drug delivery
AR123228A1 (es) 2020-08-12 2022-11-09 Servier Pharmaceuticals Llc Formas en estado sólido de un compuesto orgánico
JP2023544998A (ja) 2020-10-02 2023-10-26 ロンザ・ベンド・インコーポレーテッド 塩基性薬物の噴霧乾燥における加工助剤としての酢酸

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343548B2 (en) * 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
MX2009006806A (es) * 2006-12-22 2009-08-27 Vertex Pharma Secado por rocio fluidizado.
WO2010059239A2 (en) * 2008-11-21 2010-05-27 Millennium Pharmaceuticals, Inc Lactate salt of 4-(6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
ES2740424T3 (es) * 2009-03-13 2020-02-05 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular
AU2010259002B2 (en) * 2009-06-08 2014-03-20 Nantbio, Inc. Triazine derivatives and their therapeutical applications
US8652534B2 (en) * 2009-10-14 2014-02-18 Berry Pharmaceuticals, LLC Compositions and methods for treatment of mammalian skin
KR20210028747A (ko) * 2010-10-21 2021-03-12 메디베이션 테크놀로지즈 엘엘씨 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염
CN102827170A (zh) * 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
SG10201602862RA (en) * 2012-01-06 2016-05-30 Agios Pharmaceuticals Inc Therapeutically Active Compounds And Their Methods Of Use
US9474779B2 (en) * 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2014015422A1 (en) * 2012-07-27 2014-01-30 Ontario Institute For Cancer Research Cellulose-based nanoparticles for drug delivery
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
AU2019232825B2 (en) 2021-08-05
CN106163507B (zh) 2020-06-26
US20170007661A1 (en) 2017-01-12
MA39725B1 (fr) 2021-09-30
DK3116491T3 (da) 2021-08-09
AU2019232825A1 (en) 2019-10-10
PH12016501788B1 (en) 2016-12-19
HRP20211233T1 (hr) 2021-10-29
UA122962C2 (uk) 2021-01-27
HUE055209T2 (hu) 2021-11-29
WO2015138837A1 (en) 2015-09-17
PH12016501788A1 (en) 2016-12-19
CN112206232A (zh) 2021-01-12
SI3116491T1 (sl) 2021-12-31
MX2021001739A (es) 2021-04-19
EA202090098A1 (ru) 2020-11-30
EP3116491B1 (en) 2021-05-05
BR122023021440A2 (pt) 2023-12-12
ZA201606134B (en) 2024-01-31
PT3116491T (pt) 2021-08-10
IL247721A0 (en) 2016-11-30
MX2016011865A (es) 2017-04-13
AU2015229212A1 (en) 2016-09-22
JP6524119B2 (ja) 2019-06-05
KR20160124907A (ko) 2016-10-28
BR122023021436A2 (pt) 2023-12-12
EA034366B1 (ru) 2020-01-31
IL247721B (en) 2020-04-30
RS62178B1 (sr) 2021-08-31
JP2021088605A (ja) 2021-06-10
EP3116491A1 (en) 2017-01-18
EA201691844A1 (ru) 2016-12-30
CY1125205T1 (el) 2023-03-24
CA2942070A1 (en) 2015-09-17
NZ723860A (en) 2023-04-28
KR102458157B1 (ko) 2022-10-24
JP2017508804A (ja) 2017-03-30
CN106163507A (zh) 2016-11-23
AU2015229212B2 (en) 2019-06-20
PL3116491T3 (pl) 2022-02-07
BR112016021012B1 (pt) 2024-01-23
ES2881858T3 (es) 2021-11-30
JP2019163278A (ja) 2019-09-26
EP3116491A4 (en) 2017-11-15
LT3116491T (lt) 2021-08-10

Similar Documents

Publication Publication Date Title
IL281863A (en) Preparations containing meloxicam
BR112016021012A2 (pt) composições farmacêuticas de compostos terapeuticamente ativos.
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
EP3116492A4 (en) Pharmaceutical compositions of therapeutically active compounds
BR112016023628A2 (pt) composições farmacêuticas.
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
MA50541A (fr) Formulations pharmaceutiques
DK3529240T3 (da) Farmaceutiske forbindelser
MA42303A (fr) Formulations pharmaceutiques
BR112017013013A2 (pt) combinações de composto ativo
MA44987A (fr) Formulations de médicaments améliorées
DK3191085T3 (da) Misbrugsresistente farmaceutiske sammensætninger
DK3280447T3 (da) Farmaceutiske formuleringer
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
HK1243650A1 (zh) 包含美洛昔康的藥物組合物
DK3288967T3 (da) Farmaceutisk forbindelse
DK3089740T3 (da) Farmaceutisk sammensætning
DK2915526T3 (da) Farmaceutiske sammensætninger, der omfatter anagrelid
DK3728220T3 (da) Farmaceutiske forbindelser
DK3558261T3 (da) Farmaceutiske sammensætninger omfattende safinamid
DK3389638T3 (da) Farmaceutisk sammensætning omfattende pimobendan
DK3581582T3 (da) Farmaceutisk forbindelse
HRP20220610T8 (hr) Farmaceutski pripravci koji sadrže meloksikam

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: LES LABORATOIRES SERVIER (FR)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023021436-6 PROTOCOLO 870230091529 EM 16/10/2023 16:59.O PEDIDO FOI DIVIDIDO NO BR122023021440-4 PROTOCOLO 870230091552 EM 16/10/2023 17:20.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/03/2015, OBSERVADAS AS CONDICOES LEGAIS